Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA)
CUSIP: 70261F202
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock, par value $0.0001
- Shares outstanding
- 24,858,270
- Total 13F shares
- 78,704
- Share change
- +1,542
- Total reported value
- $99,102
- Price per share
- $1.30
- Number of holders
- 7
- Value change
- -$116,583
- Number of buys
- 4
- Number of sells
- 4
Quarterly Holders Quick Answers
What is CUSIP 70261F202?
CUSIP 70261F202 identifies KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 70261F202:
Top shareholders of KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| PD Joint Holdings, LLC Series 2016-A |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,608,696
|
$1,124,348 | — | 22 Oct 2022 | |
| Eric Shahinian |
3/4/5
|
Member of 10% owner group |
—
class O/S missing
|
1,788,415
|
$770,807 | — | 28 Sep 2022 | |
| Israel Maxx Abramowitz |
3/4/5
|
Not a 10% owner |
—
class O/S missing
|
1,051,575
|
$453,229 | — | 14 Sep 2021 | |
| Dean Lazer |
3/4/5
|
Not a 10% owner |
—
class O/S missing
|
902,600
|
$389,021 | — | 14 Sep 2021 | |
| Eric Lazer |
3/4/5
|
Not a 10% owner |
—
class O/S missing
|
902,600
|
$389,021 | — | 14 Sep 2021 | |
| ARMISTICE CAPITAL, LLC |
13D/G
13F
|
Company |
5%
|
142,082
|
$240,119 | +$14,019 | 31 Mar 2025 | |
| Lawrence Steinman |
13D/G
|
— |
3.1%
|
83,858
|
$141,720 | $0 | 01 Mar 2025 | |
| Dr. Yassine Bendiabdallah |
3/4/5
|
Chief Operating Officer, Director |
—
class O/S missing
|
300,000
|
$129,300 | — | 14 Sep 2021 | |
| David Delaney |
3/4/5
|
Member of 10% owner group |
—
class O/S missing
|
227,521
|
$98,062 | — | 17 Oct 2022 | |
| UBS Group AG |
13F
|
Company |
0.05%
|
12,868
|
$40,534 | — | 31 Dec 2024 | |
| Avi Geller |
3/4/5
|
Member of 10% owner group |
—
class O/S missing
|
54,644
|
$23,552 | — | 19 Aug 2022 | |
| Kepos Capital LP |
13F
|
Company |
—
class O/S missing
|
334,600
|
$12,000 | — | 31 Dec 2024 | |
| Warberg Asset Management LLC |
13F
|
Company |
—
class O/S missing
|
254,701
|
$8,813 | — | 31 Dec 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
1,886
|
$5,941 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
1,000
|
$3,150 | — | 31 Dec 2024 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
250
|
$1,000 | — | 31 Dec 2024 | |
| Marex Group plc |
13F
|
Company |
—
class O/S missing
|
25,000
|
$925 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
150
|
$473 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
8
|
$25 | — | 31 Dec 2024 | |
| CLEAR STREET LLC |
13F
|
Company |
—
class O/S missing
|
71
|
$2 | — | 31 Dec 2024 | |
| Graeme Martin Currie |
3/4/5
|
Chief Development Officer |
—
class O/S missing
|
5,938
|
— | — | 01 Mar 2024 |
Institutional Holders of Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA) as of Q1 2025
As of 31 Mar 2025,
Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA) was held by
7 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
78,704 shares.
The largest 7 holders included
AdvisorShares Investments LLC, CITIGROUP INC, UBS Group AG, Hurley Capital, LLC, Tower Research Capital LLC (TRC), JPMORGAN CHASE & CO, and BANK OF AMERICA CORP /DE/.
This page lists
7
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
7
Q1 2025 holders
7
Holder diff
0
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.